cancer immunotherapy

German Merck Licenses Fusion Protein to PDS

Germany‘s Merck has granted an exclusive license for the tumor-targeting IL-12 fusion protein currently known as M9241 to PDS Biotechnology Corporation, a US-based clinical-stage immunotherapy company with a growing pipeline of targeted immunotherapies for cancer and infectious disease.

Merck and Pfizer Get FDA Orphan Drug Status

Bavarian Nordic Wins Janssen Ebola Subcontract

Amgen to Buy Dezima Pharma, Collaborates with Xencor

Novartis Boosts Cancer Immunotherapy Research Efforts

Novartis Acquires U.S. Cancer Specialist CoStim

Merck, Ono To Jointly Develop Oral Multiple Sclerosis Drug, Cancer Immunotherapy